Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Choline alfoscerate for mild cognitive impairment with vascular damage
2020-000576-38Phase 4Active
- Sponsor
- University of Camerino
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of choline alfoscerate in Mild Cognitive Impairment (MCI) (2 arms), sponsored by University of Camerino. Started Feb 2022; status: active.
02
Drugs
choline alfoscerate
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on 2020-000576-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000576-38.